Comparative Pharmacology
Head-to-head clinical analysis: ESTRADIOL VALERATE AND DIENOGEST versus ESTRONE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ESTRADIOL VALERATE AND DIENOGEST versus ESTRONE.
ESTRADIOL VALERATE AND DIENOGEST vs ESTRONE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Estradiol valerate is a prodrug of estradiol, an estrogen that binds to estrogen receptors (ERα and ERβ) to regulate gene transcription, promoting endometrial growth and suppressing gonadotropins. Dienogest is a progestin with partial antiandrogenic activity, binding to progesterone receptors to inhibit endometrial proliferation and ovulation, and reducing androgen synthesis.
Estrone is a natural estrogen that binds to estrogen receptors (ERα and ERβ) in target tissues, modulating gene expression and exerting estrogenic effects on reproductive, skeletal, and cardiovascular systems.
One tablet (2 mg estradiol valerate and 3 mg dienogest) once daily orally, without interruption, following the first day of menstrual cycle.
For menopausal hormone therapy: 0.625-5 mg orally once daily; or 0.1-0.5 mg transdermally once weekly; or 2.5-5 mg intramuscularly every 2-4 weeks.
None Documented
None Documented
Clinical Note
moderateEstrone + Gatifloxacin
"The risk or severity of adverse effects can be increased when Estrone is combined with Gatifloxacin."
Clinical Note
moderateEstrone sulfate + Gatifloxacin
"The risk or severity of adverse effects can be increased when Estrone sulfate is combined with Gatifloxacin."
Clinical Note
moderateEstrone + Rosoxacin
"The risk or severity of adverse effects can be increased when Estrone is combined with Rosoxacin."
Clinical Note
moderateEstrone sulfate + Rosoxacin
Estradiol valerate: Terminal half-life of estradiol is 13-15 hours; valerate ester is rapidly hydrolyzed, so systemic estradiol half-life applies. Dienogest: Terminal half-life ~8-10 hours, increasing to ~12-14 hours with multiple dosing due to competitive inhibition of CYP3A4.
Terminal elimination half-life is 24-36 hours; due to enterohepatic recirculation and slow clearance of conjugates, clinical effects persist for several days after discontinuation.
Estradiol valerate: Renal (primarily as glucuronide and sulfate conjugates) ~40%, Fecal ~60%. Dienogest: Renal ~60% (mostly unchanged), Fecal ~30%.
Renal (approximately 60-80% as glucuronide and sulfate conjugates), biliary/fecal (20-40%)
Category D/X
Category C
Estrogen
Estrogen
"The risk or severity of adverse effects can be increased when Estrone sulfate is combined with Rosoxacin."